Localized Amyloidosis of the Head and Neck by Işil Adadan Güvenç
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1. Introduction 
Amyloidosis is a benign, slowly progressive condition characterized by the presence of 
extracellular fibrillar proteins in a variety of organs and tissues. It can be categorized as 
systemic or localized. Head and neck involvement can be seen in both systemic and 
localized amyloidosis. Systemic amyloidosis results in involvement of many organs, and 
shortens life expectancy, whereas localized amyloidosis is usually benign (Yiotakis et al., 
2009). In this extensive review, the presentation, diagnosis and treatment modalities of 
localized amyloidosis of the head and neck will be discussed. 
2. Localized amyloidosis of the head and neck  
Virchow, in 1851, was the first to use the term amyloid because of its starchlike reaction 
when treated with iodine and sulfuric acid. In 1842, however, Von Rokitansky was the first 
to identify this material in the liver and spleen. Symmers classified amyloidosis clinically as: 
primary amyloid (localized or general); secondary amyloid (localized or general); amyloid 
associated with multiple myeloma; and hereditary or familial amyloid. In systemic or 
generalized disease, amyloid is deposited in many organ systems and life expectancy is 
shortened (Kennedy & Patel, 2000). The mean survival of patients with systemic forms is 
between 5 to 15 months, whereas those with localized forms have an excellent prognosis 
(Fahrner et al., 2004). Approximately 9% of amyloidosis cases are localized (Kyle & Bayrd, 
1975). In localized amyloidosis of the head and neck, deposition of amyloid may be 
observed in individual organs without any systemic involvement. The progressive 
accumulation of amyloid deposits interferes with the normal structure of affected tissues 
resulting eventually in impairment of their function (Yiotakis et al., 2009). Life expectancy is 
not affected unless an enlarging laryngotracheal lesion goes unattended (Kennedy & Patel, 
2000). 
Clinically, amyloidosis is divided into two main categories, systemic and localized. Types of 
systemic amyloidosis are AL, AA, familial and senile amyloidosis. 
AL amyloidosis, formerly called, primary amyloidosis is seen in progressive systemic 
disease, plasma cell dyscrasia/multiple myeloma, and most localized forms of amyloidosis. 
AL amyloid associated with plasma cell dyscrasia is the most common form of amyloidosis, 
accounting for 75% of cases in the United States (Penner & Muller, 2006). 
AA amyloidosis, formerly called, secondary amyloidosis occurs in association with chronic 
inflammatory disorders, chronic infections, and accounts for only 5% of all amyloid cases. 
The amyloid fibril protein is derived from the circulating acute phase protein known as 
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serum amyloid A (Panda et al., 2007). AA amyloidosis shows a predilection for the spleen, 
liver, kidney, lymph nodes, and adrenals, although no organ system is spared. AA 
amyloidosis may also occur in association with Hodgkin disease, genitourinary or 
gastrointestinal malignancies (Penner & Muller, 2006). In systemic amyloidosis, proteinuria 
with nephrotic syndrome is often the first symptom; other manifestations include peripheral 
neuropathies, dementia and cognitive dysfunction, and organ enlargement, especially of the 
liver, kidney, spleen and heart (Sipe & Cohen, 1998). Macroglossia is most frequently noted 
in the head and neck region. Other nonspecific signs and symptoms such as fatigue, weight 
loss, orthostatic hypotension, diarrhea, skeletal muscle pseudohypertrophy, skin papules or 
plaques, arrhythmias, renal failure, congestive heart failure and carpal tunnel syndrome can 
be seen. Renal failure is the major cause of death in systemic amyloidosis. Sudden death 
secondary to cardiac arrythmias is also common (Nandapalan et al., 1998). The median 
survival reported by Kyle and Greipp in 229 cases of systemic amyloidosis was 13 months 
for patients with amyloidosis only, and 5 months for those with amyloidosis and myeloma 
(Kyle & Greipp, 1983). 
 
Amyloid 
Protein 
Protein Precursor Clinical Syndrome 
AA apoSAA Reactive (secondary) 
Familial Mediterranean fever 
Muckle-Wells syndrome 
AL Igǌ, Igǋ Idiopathic (primary) 
Multiple myeloma 
Local nodular 
AH Ǆ1 heavy chain Macroglobulinemia 
A ǃ2M ǃ2 microglobulin Chronic hemodialysis arthropathy 
A ǃ ǃ-protein precursor Alzheimer’s disease 
Down’s syndrome 
Hereditary cerebral angiopathy with bleeding 
APrP Prion protein  Creutzfeldt-Jacob disease 
Gerstmann-Straussler syndrome 
Kuru 
AIAPP Amyloid insulin 
polypeptide 
Diabetes mellitus type 2 
Insulinoma 
AANF Atrial natriuretic 
factor 
Senile cardiac amyloid 
ATTR Transthyretin FAP; multiple point mutations 
Senile systemic cardiac 
AGel Gelsolin FAP-Finnish 
AApoA1 Apolipoprotein A1 FAP-Iowa (Irish) 
ACys Cystatin C Hereditary cerebral angiopathy with bleeding 
AFibA Fibrinogen A ǂ Nonneuropathic hereditary amyloid with renal 
disease 
ALys Lysozyme Nonneuropathic hereditary amyloid with renal 
disease 
Table 1. Abbreviated classification of amyloid (Sipe & Cohen, 1998) 
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ǃ2M amyloidosis is associated with patients who are maintained on hemodialysis for more 
than 7 years. Familial transthyretin–associated (ATTR) patients with normal plasma 
transthyretin develop senile systemic amyloidosis with predominant cardiac involvement, 
whereas patients with genetically variant transthyretin develop familial amyloid 
polyneuropathy (FAP), usually with systemic amyloidosis (Berg et al., 1993; Kennedy & 
Patel, 2000). Table 1 shows the most common amyloid proteins and associated clinical 
syndromes (Sipe & Cohen, 1998). 
Approximately 9% to 15% of amyloidosis is of the localized type, which usually consists of 
AL amyloid (Passerotti et al., 2008). In localized idiopathic AL amyloidosis, localized 
deposition of amyloid is regarded to be the result of local synthesis rather than the 
deposition of light chains produced elsewhere in the human body (Yiotakis et al., 2009). The 
benign nature of localized amyloidosis suggests that a localized clone of plasma cells 
producing an amyloidogenic light chain may represent the pathogenetic mechanism of this 
disease, which appears to be a form of plasma cell dyscrasia (Berg et al., 1993). 
Histologically, amyloid is extracellular deposits of insoluble, homogenous, amorphous, 
acellular, eosinophilic and proteinaceous material with a well-defined ǃ-pleated sheet 
ultrastructure (Figure 1). Lymphocytes, plasma cells, and foreign body giant cells may be 
seen in the surrounding tissue in localized amyloidosis. Infiltration of plasma cells observed 
near localized amyloid deposits suggests local production of the amyloid precursor protein.  
Immunohistochemical and molecular genetic studies have characterized clonal plasma cell 
populations associated with local amyloid deposits, and have matched the amyloid protein 
with DNA sequencing of the plasma cell clone (Biewend et al., 2006). These abundant 
plasma cells are not seen in systemic AL amyloidosis, but rather the circulating light chain 
proteins are gathered in specific organs. Giant cells frequently accompany localized amyloid 
deposits. The role of these giant cells is unclear; they may actively participate in amyloid 
fibril formation by uptake and modification of the precursor protein, or they may be part of 
a foreign body reaction in an attempt by the body to remove amyloid (O’Halloran & Lusk, 
1994; Xu et al., 2005). 
Classically, amyloid can be distinguished from other eosinophilic infiltrates via its apple-
green birefringence when stained with Congo red and viewed under polarized light (Figure 
2). This feature is specific but not sensitive. If the specimen loses its affinity for Congo red 
after exposure to potassium permanganate, this suggests an AA type amyloid deposit 
(Pentenero et al., 2006). Immunohistochemistry can differentiate kappa light chains from 
lambda light chains in AL type amyloidosis as well as excluding AA (inflammation-derived) 
and ATTR (transthyretin-derived) amyloid chains. Because of deposition of the variable 
regions of light chains, AL amyloid stains positive with commercially available antibodies 
only in approximately 40% of cases. Thus, negative immunostaining does not exclude AL 
amyloid. Isolation of amyloid with biochemical characterization by amino acid sequencing 
is the best way to confirm the AL type, but this is a very elaborate and time-consuming 
method and is not useful in normal practice (Bartels et al., 2004). Eventually these studies do 
not have much influence on patient management, since the number of additional biopsies 
and the treatment of localized amyloidosis do not differ whether the type of amyloidosis is 
known or not. Electron microscopy shows that all amyloid subtypes are composed of 7.5–10 
nm wide linear, nonbranching tubular protein fibrils loosely arranged in a meshwork 
(O’Halloran & Lusk, 1994). 
It is important to perform detailed investigations at diagnosis to rule out a systemic process. 
General blood examination (hemoglobin, creatinine, total protein, albumin, bilirubin, 
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alkaline phosphatase), general urine examination (creatinine clearance, proteinuria), ECG, 
echocardiography, abdominal USG should be undertaken (Bartels et al., 2004). Serum and 
urine analysis to detect the presence of a monoclonal paraprotein composed of amyloid light 
chains should also be performed. Serum or urine “Bence Jones proteins” will be found in up 
to 88% of patients with primary systemic amyloidosis and 100% of patients with multiple 
myeloma-associated systemic amyloidosis (Fahrner et al., 2004). If electrophoresis fails to 
demonstrate paraproteins, immunelectrophoresis should be considered (Kyle & Bayrd, 
1975). Collagen vascular diseases, tuberculosis, and multiple myeloma (rheumatoid factor, 
antinuclear antibody, tuberculosis skin test, and chest radiograph) should also be excluded 
(Friedman et al., 2002). Some authors advocate extensive investigations for patients who 
present with localized upper aerodigestive tract amyloidosis. Invasive procedures including 
labial salivary gland (LSG) biopsy, aspiration of abdominal fat, bone marrow biopsy, and 
rectal biopsy (positive in 84% of the cases) have been suggested as methods to exclude 
systemic amyloidosis. However, as the diagnostic yield is very low, some authors believe 
that invasive investigations are not indicated (Green et al., 2000). Fine-needle aspiration of 
abdominal fat pad (FNAFP) is less invasive compared to tissue biopsies and in a recent 
report, the estimated sensitivity and specificity of FNAFP was found to be 75% and 92%, 
respectively. Based on results of follow-up biopsies and compelling clinical findings, others  
 
 
Fig. 1. In an excisional biopsy of localized amyloidosis of nasopharynx, bright pink 
homogenous, amorphous, acellular, eosinophilic material is seen in the submucosa 
(hematoxylin eosin, X40) (Özdemir et al., 2010) 
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have reported specificity of 100% and sensitivity in the range of 58–88%. The overall 
simplicity and ease of the procedure makes FNAFP the initial technique of choice for the 
diagnosis of systemic amyloidosis (Ansari-Lari & Ali SZ, 2004). 123I-SAP scintigraphy is 
another non-invasive test to confirm or rule out occult systemic amyloidosis. However, in a 
few cases, 123I-SAP scintigraphy can be normal despite systemic amyloidosis with small 
amyloid deposits. The scintigraphy combined with LSG biopsy gives the clinician valuable 
information about the local or systemic character of amyloid deposits (Maulin et al. 1997). 
 
 
Fig. 2. Apple-green birefringence under polarized light (Congo-red, polarization 
microscope, ×20) (Akyıldız et al., 2009) 
When the diagnosis of localized amyloidosis is finally validated, the risk of further local 
progression exists, but the risk of systemic progression is low. In fact only three studies have 
possibly reported localized amyloidosis progressing to systemic disease. Some confusion 
still exists in the literature, since submucosal progression from laryngeal deposits to the 
tracheal, bronchial, or gastrointestinal tract is sometimes equated with systemic 
involvement. In the absence of a systemic involvement or a hematological malignancy, 
multifocal involvement of the aerodigestive tract should not be considered as systemic 
dissemination. In this regard, a full endoscopic assessment of the involved tract is necessary 
in order to clearly determine the number of sites affected by the process, to exclude an 
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associated neoplasm and to anticipate the outcome. Due to the markedly shortened life 
expectancy in patients with systemic forms of amyloidosis, it is obligatory to differentiate 
systemic disease from the localized type (Paccalin et al., 2005). 
Magnetic resonance imaging (MRI) is the technique of choice to demonstrate the most 
specific features of amyloidosis. Typically, the amyloid deposits have intermediate T1- 
weighted signal intensity and low T2-weighted signal intensity, similar to skeletal muscle. 
This is secondary to the ǃ-pleated structure of the amyloid deposits that occurs as protein 
fibrils in a parallel sheetlike configuration, similar to the organization of skeletal muscle 
fibers (Gilad et al., 2007). MRI taken before and after excision, helps in the evaluation and 
follow-up of the deposits, and can prevent further endoscopic examination (Chin et al., 
2004). 
Computed tomography (CT) scanning can discriminate between localized and diffuse 
disease in patients with amyloidosis of the respiratory tract (Chin et al., 2004). On CT scans, 
amyloid deposits appear as relatively well-defined, submucosal, homogenous masses, 
usually demonstrating different forms of calcification (Figure 3).  
 
 
Fig. 3. CT scan of a lesion on the right side of the tongue base. Calcification is seen within 
the lesion. (Akyıldız et al., 2009) 
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Although the amyloid itself does not enhance with contrast material administration, 
peripheral enhancement in the region of the amyloid deposits has been noted. This may be 
caused by the foreign-body giant cell reaction that is evoked around the amyloid deposits. 
The lack of enhancement of the amyloid deposits helps to distinguish them from cellular 
tumors, all of which enhance to varying degrees (Chin et al., 2004). 
The low risk of subsequent systemic disease does not mean that localized amyloidosis is 
always benign. Although most patients remain free of disease, a few others have 
symptomatic recurrences, sometimes after many symptom-free years. Complications and 
fatal local progression have been reported despite optimal symptomatic treatment in 
respiratory tract and laryngeal amyloidosis because of recurrent obstruction, progressive 
respiratory failure or fatal hemorrhage (Gean-Marton et al., 1991). 
Localized amyloidosis in the head and neck is a rare and benign disease. However 90% of 
the patients with systemic amyloidosis will develop amyloid deposits in the upper 
aerodigestive tract. Owing to its poor prognosis, the latter condition should be differentiated 
from primary localized amyloidosis of the head and neck. Localized amyloidosis may 
involve any site in the head and neck including the orbit, nose, paranasal sinuses, 
nasopharynx, oropharynx, tonsils, oral cavity, salivary glands, tongue, tracheobronchial tree 
and larynx (Passerotti et al., 2008; Penner & Muller S, 2006). The larynx is the most common 
site of involvement and is rarely associated with systemic disease. In contrast, amyloid 
macroglossia is usually associated with systemic AL amyloidosis, either plasma cell 
dyscrasia or multiple myeloma. Most other locations in the head and neck are extremely 
rare with limited cases reported (Penner & Muller S, 2006). 
3. Localized laryngeal amyloidosis 
Localized laryngeal amyloidosis accounts for 0.2% to 1.5% of benign laryngeal tumors (Ma 
et al., 2005). The first case of localized laryngeal amyloidosis was documented by Borow in 
1873. McAlpine and Fuller, in a review of the literature, found 235 cases of localized 
amyloidosis of the upper and lower respiratory tracts, and the larynx was involved in 177 
cases (75%) (Nandapalan et al., 1998, as cited in McAlpine & Fuller, 1964). Until 1990, only 
approximately 300 cases of upper airway amyloidosis were reported in the literature. This 
condition most commonly occurs in the fourth to sixth decades of life, with a male-female 
predominance of 3:1 (Ma et al., 2005). 
The precise etiology and pathogenesis of laryngeal amyloidosis remain unknown. There is 
no definite established link with smoking, drinking, vocal abuse or recurrent infection (Ma 
et al., 2005). A large percentage of these patients also have significant reflux esophagitis. 
Amyloid deposits can result from chronic inflammatory process, and gastroesophageal 
reflux may be the cause in these cases.  
Laryngeal amyloidosis most frequently presents with progressive dysphonia. Other 
complaints are dysphagia, dyspnea with exertion, choking, occasional aspiration, cough, 
fullness in the throat or globus sensation and rarely, hemoptysis (Bartels et al., 2004; 
Kennedy& Patel, 2000; Yiotakis et al., 2009). 
The gross appearance usually suggests a mucosally covered mass. The initial diagnosis is 
thought to represent a malignant neoplasm in most patients. Furthermore, at laryngoscopy 
and frozen section biopsy, the diagnosis may suggest only granulation tissue or a foreign 
body type of reaction and it may not be until after the permanent sections are analyzed that 
amyloidosis is considered (Kennedy& Patel, 2000). 
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The lesion is usually a firm, nonulcerated yellow, orange or gray submucosal nodule, mass 
or a pedunculated polypoid lesion. Amyloid deposits are most commonly located in the 
false vocal cords (55%) and ventricles (36%), less commonly in the subglottis (36%), vocal 
folds (27%), the aryepiglottic folds (23%) and anterior commissure (14%) (Mitrani & Biler, 
1985). It is frequent to have multiple laryngeal sites, or even, that of the aerodigestive tract, 
and tongue and trachea are the ones most frequently associated with laryngeal amyloidosis 
and, in such cases, systemic involvement is also more common (Passerotti et al., 2008). A 
case of laryngocele caused by localized laryngeal amyloidosis has been reported in the 
literature (Cankaya et al., 2002). Only one case of localized AL-type hypopharyngeal 
amyloidoma has been reported to date. (Ghekiere et al., 2003). Two other cases of localized 
amyloidosis of hypopharynx were secondary to multipl myeloma (Chadwick et al, 2002; 
Hammami et al, 2010) 
Four histological patterns of laryngeal amyloidosis have been described. These include 
amorphous random masses, deposits around blood vessels, deposits in continuity with the 
basilar membrane of seromucinous glands, and deposits within adipose tissue (Gallivan & 
Gallivan, 2010).  
Laryngeal amyloidosis is usually associated with amyloid protein of the light chain 
(amyloid L; AL) type. Restricted light chain staining (lambda or kappa) in both plasma cells 
and the amyloid has been observed in cases of laryngeal amyloidosis. In one series, more 
than 60% of laryngeal deposits displayed a lambda light chain staining pattern, and 25% a 
kappa pattern. (Lewis et al., 1992; Ma et al., 2005). 
Diagnosis should focus on evaluating the extent of local amyloidosis and on ruling out 
systemic involvement. Macroscopic examination of the larynx should be performed by 
indirect videolaryngostroboscopy. A thorough voice analysis is also required.  
Radiological examination involves CT and MRI. On CT scans, laryngeal amyloidosis 
presents with submucosal and homogeneous amyloid deposits which are not associated 
with the cartilage changes. These deposits are firm lesions that tend to occur in the 
supraglottic larynx (Figure 4), although all laryngeal sites may be affected (Bartels et al., 
2004). CT two-dimensional reconstruction images, along with their axial views, are found to 
be more helpful than any other scan in mapping the location of the amyloid before surgery 
as well as in planning the time of the surgery (Kennedy& Patel, 2000). The differential 
diagnosis includes other submucosal diseases such as laryngeal sarcoidosis, lymphoma and 
pseudotumor. Submucosal lesions such as paragangliomas and hemangiomas are more 
localized on CT scans and MR images, and the entire lesion enhances rather than periphery 
(Bartels et al., 2004). However, even though the radiological studies are helpful, amyloidosis 
is usually not included in the differential before the material for biopsy is obtained by direct 
laryngoscopy (Kennedy & Patel, 2000). 
Systemic work-up should include a thorough history (including family history), physical 
examination (enlargement of spleen or liver, cardiac failure, edema), laboratory screening 
(levels of hemoglobin, serum creatinine, bilirubin, total protein, albumin, alkaline 
phosphatase, and proteinuria and a search for monoclonal proteins in serum and urine). 
ECG, echocardiography, and at least one other biopsy of a different site of the body, 
preferably the rectum or abdominal subcutaneous fat tissue (Bartels et al., 2004). Use of 123I-
SAP scintigraphy may be helpful, especially if combined with labial biopsy (Maulin et al., 
1997). 
Diagnostic work-up should also look for collagen vascular diseases, tuberculosis, and 
multiple myeloma (rheumatoid factor, antinuclear antibody, tuberculosis skin test, chest  
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Fig. 4. Amyloidosis localized in supraglottic larynx. In this case thyroid cartilage appeared 
intact and no nodal involvement was detected (Yiotakis et al., 2009) 
radiograph). The differential diagnosis should also include metastatic medullary thyroid 
cancer, laryngeal sarcoidosis, benign laryngeal polyps, laryngeal malignancies, benign 
minor salivary gland tumors and chondromas (Friedman et al., 2002) 
The larynx is rarely the first location of systemic amyloidosis; however, systemic 
amyloidosis should never be ruled out from the differential diagnosis because of its 
potentially poor prognosis. In a case with localized laryngeal amyloidosis, systemic 
amyloidosis developed after an 8-year period, therefore yearly visits with a follow-up 
period of at least 10 years is recommended. Yearly monitoring of the presence of 
monoclonal free light chains in serum and urine may be helpful in detecting progression 
into systemic AL amyloidosis at an earlier stage of the disease (Bartels et al., 2004).  
Laryngeal involvement may be a part of laryngo-tracheobronchial amyloidosis (LTBA) 
causing airway obstruction, hemoptysis, chronic cough, recurrent respiratory infections, 
dysphonia and dysphagia. LTBA is usually a primary, localized form of the disease, with 
deposits of AL amyloid fibrils. This evidence, together with the presence of plasma cells in 
and around amyloid deposits, may suggest that localized plasma cell dysfunction is 
responsible for this pathology. The precise etiology of primary localized airway amyloidosis 
still remains unclear, and the most recent hypothesis about its origin involves derangement 
of immunoregulation after recurrent or prolonged antigen challenge. Others have 
speculated that idiopathic production of structurally abnormal immunoglobulins by 
monoclonal plasma cells may overwhelm the clearing mechanisms leading to deposition of 
their cleavage products in the airway submucosa.  
Classifying patients in a series of 32 LTBA cases showed purely laryngeal involvement in 
12.5% of cases, isolated tracheal localization in 3% of cases, laryngo-tracheal amyloidosis (or 
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“proximal airway disease”) in 28% of cases, tracheobronchial disease (or “mid and distal 
airway disease”) in 44% of cases, and extensive involvement of the entire 
laryngotracheobronchial tree in 12.5% of cases. A full endoscopic assessment of the involved 
tract clearly defines the number of sites affected by the process. 
The endoscopic appearance of LTBA lesions can be classified as submucosal plaques and 
nodules, pseudotumor or tumor-like appearance, circumferential wall thickening. These 
appearances represent different stages of the same process of amyloid deposition. In fact, it 
seems to start with the formation of submucosal yellowish plaques, seen nearly everywhere 
in the tracheobronchial tree. Then lesions grow progressively in a confluent manner leading 
to a circumferential thickening or pseudotumor appearance. It is believed that these 
different endoscopic appearances have no prognostic implications, but effect the surgical 
options. In a pseudotumor mass or a circumferential wall thickening, mechanical resection 
and/or dilatation coupled with transmucosal Nd:YAG laser treatment with low power and 
high energy density are recommended. On the other hand, submucosal plaques, particularly 
when located at the glottic or subglottic levels, should be treated by a mucosa-sparing 
approach or by CO2 laser, thus minimizing scar tissue formation and subsequent 
complications (Piazza et al., 2003). 
Localized laryngeal amyloidosis is a slowly progressive disease that should be treated 
according to the complaints of the patient. The indication for treatment is not determined by 
the presence of amyloid deposits, but the symptoms these deposits result in, such as 
dysphonia or dyspnea. Bronchoscopy is important to identify subglottic amyloid deposits 
and more distal tracheal or bronchial lesions. While the prognosis for laryngeal amyloidosis 
is usually good, death has rarely been reported. This usually occurs from diffuse 
tracheobronchial disease with pulmonary failure (Lewis et al., 1992). 
The primary treatment described in localized laryngeal amyloidosis is endoscopic surgical 
removal of deposits that interfere with laryngeal or airway function, although extensive 
surgical procedures have been performed, depending on the size of the lesions. The location 
and size of the amyloid deposits should determine the surgical instruments of choice. 
Biopsy specimens are preferably removed by cold endoscopic excision. The specimens can 
be examined more minutely if no carbonization is present. Cold endoscopic excision is 
preferable for the removal of small deposits and those located at critical anatomic sites such 
as the true vocal cords. In these cases, a standard cordotomy is performed, after which the 
cheese-like contents can be taken out of the subepithelial space, and then the epithelial flap 
is glued back. In the same way, coring out subglottic lesions has a lasting and effective 
result. CO2 laser or powered instrumentation is usually used in supraglottic deposits. The 
epithelium is excised with these techniques. This may be the reason why supraglottic lesions 
tend to recur (Bartels et al., 2004).  
Because of the propensity of amyloid to infiltrate blood vessels, cold resection of amyloid 
lesions may be complicated by bleeding. CO2 laser excision may be advantageous, but if 
used in very extensive lesions, there may be scarring. In very large lesions, external 
approaches, employing laryngofissure for treatment of diffuse subglottic and tracheal 
amyloidosis have been used. Repeated excision and curettage may be necessary to achieve 
stabilization of lesions and subsequent decannulation of those patients who are tracheotomy 
dependent (Gallivan & Gallivan, 2010). Large supraglottic amyloid deposits, can be handled 
by supraglottic laryngectomy, or, by a more conservative approach, a lateral supraglottic 
procedure can be used (Kennedy & Patel, 2000). Local or systemic steroids are ineffective in 
controlling or reversing lesions of amyloidosis.  
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Gallivan and Gallivan report in their article that at the airway clinic they work with, 8 of 10 
patients (3 laryngeal and 7 tracheobronchial recurrent amyloidosis cases) had achieved 
disease stability with low dose radiation. (Gallivan & Gallivan, 2010). In another recent case 
report, a case of localized laryngeal amyloidosis involving false vocal cord was treated with 
surgical debulking and adjuvant external beam radiation to a dose of 45 Gy (Neuner et al., 
2010). 
There have been several proposed mechanisms by which radiation exerts its effects on 
amyloid deposits. One theory is that localized radiation therapy has a destructive effect on 
local abnormal plasma cells, which tend to be low dose radiation sensitive, as has been 
shown in patients with multiple myeloma and plasmacytomas. However, the amyloid 
deposits in laryngo-tracheobronchial amyloidosis contain scarce plasma cells, so a radiation 
effect on plasma cell function or turnover is unlikely to be the only mechanism of action. 
Other possibilities include a radiation effect on local vascular structures or induction of 
immune responses against the deposits by causing local inflammation. In addition, there 
may be other blood, tissue, or pH factors in the local milieu that mediate the response 
(Neben-Wittich et al., 2007). 
Localized laryngeal amyloidosis tends to recur and it usually takes a number of years until 
the disease is stabilized. A detailed history of current symptoms and local examination of 
the larynx should be encountered with yearly follow-ups, and local recurrences should be 
treated as conservative as possible. There has been no report of malignant change in 
amyloid tumor however one must be aware of the possibility of a subsequent development 
of systemic amyloidosis (Friedman et al., 2002). 
4. Localized nasopharyngeal amyloidosis 
Localized amyloidosis occurs most commonly in the head and neck region. Among the 
sites, larynx is affected most frequently (61%), followed by oropharynx (23%), trachea 
(9%), and orbit (4%). Only 3% of cases occur in the nasopharynx. Up to 2007 there were 
only 14 reported cases (Panda et al., 2007). A Pubmed search up to the present revealed 4 
more cases including the case we had reported in 2010. (Geller et al., 2010; Özdemir et al., 
2010; Passerotti et al., 2008; Zhuang et al., 2015) Table 2 shows a list of all of the reported 
cases.  
The presentation of head and neck amyloidosis varies according to the site of involvement. 
A patient with nasopharyngeal amyloidosis may present with postnasal discharge, nasal 
obstruction, recurrent epistaxis (due to vessel wall invasion), dysphagia, foreign body 
sensation in the throat, voice change, eustachian tube dysfunction and secondary ear 
problems such as conductive hearing loss due to middle ear effusion. Lesions appear as 
yellowish, mucosa covered, irregular polypoidal masses (Patel et al., 2002). 
On CT scan, amyloid deposits appear as relatively well-defined, submucosal, homogenous 
masses, usually demonstrating different forms of calcification (Figure 5). The mass exhibits 
minimal, if any, enhancement after administration of contrast. On MRI, the submucosal 
location and distinctive hypointensity on T2-weighted images excludes many of the other 
differential diagnosis. (Gean-Marton et al., 1991) Dynamic MR further defines the vascular 
changes due to localized amyloid deposition (Asaumi et al., 2001). 
Nasopharyngeal amyloidosis is generally a slow growing, benign tumor, but it may be 
locally aggressive and produce osteolysis and even invade the skull base. CT and MRI are 
helpful in revealing any bony destruction or intracranial extension (Patel et al., 2002). 
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Authors Year Age/Sex Site of Involvement Symptoms 
Kramer  1935 - NF Nasal obstruction 
Johner 1972 - NF Nasal obstruction 
Simpson 1984 29/F NF Postnasal discharge, glue ear 
Zack Zonk 1984 14/M NF Hearing loss, glue ear 
Gean Marton  1991 - NF (3 cases) Nasal obstruction, glue ear 
Hegarty 1993 - NF with skull base erosion Nasal obstruction, postnasal discharge 
Panda 1994 82/M NF Oral bleeding 
Dominguez 1996 13/F NF and soft palate Nasal obstruction, oral bleeding 
Lim 1999 42/F NF Nasal obstruction 
Pitkaranta 2000 - NF Nasal obstruction 
Patel 2002 - NF Hearing loss, glue ear 
Zhuang 2005 - NF and cervical LN Nasal obstruction, cervical mass 
Panda 2007 43/M NF, oropharynx Nasal obstruction, foreign body 
sensation of throat 
Passerotti 2008 55/F NF, Tonsil pillar, larynx Hoarseness, dysphonia, dysphagia 
Geller 2010 62/F NF and nasolacrimal duct Nasolacrimal duct obstruction 
Özdemir 2010 67/F NF and cervical LN Nasal obstruction, cervical mass 
F: Female, M: Male, NF: Nasopharynx, LN: Lymph node 
Table 2. Reported cases of nasopharyngeal amyloidosis 
Diagnosis of nasopharyngeal amyloidosis is made with histopathological examination of 
amyloid deposits in biopsy specimens as mentioned earlier. Systemic involvement should 
be ruled out. In the absence of a systemic disease, localized nasopharyngeal amyloidosis has 
an excellent prognosis.  
Surgery is reported to be the choice of therapy. Transpalatal approach or nasopharyngeal 
curettage is preferred (Özdemir et al., 2010). Bleeding due to the loss of vascular integrity 
caused by amyloid infiltration of the blood vessels may be a major complication during 
surgery (Patel et al., 2002). Excision of the amyloid deposits should only be considered if 
they cause morbidity. However if localized amyloidosis do not cause morbidity, 
conservative treatment with careful observation is suggested (Domínguez et al., 1996). 
In the English literature two cases of localized nasopharyngeal amyloidosis associated with 
lymph node involvement in the neck are reported (Özdemir et al., 2010; Zhuang et al., 2005). 
This presentation mimics nasopharyngeal carcinoma with neck metastases. In such a case, 
diagnosis of localized amyloidosis should be confirmed with biopsy of nasopharyngeal 
mass and fine needle aspiration biopsies of the neck masses. If asymptomatic, the removal of 
the neck masses showing amyloid deposits is not necessary. 
Nasopharyngeal amyloidosis may coexist with carcinoma of nasopharynx. In a series of 434 
cases of nasopharyngeal carcinoma, amyloid deposits were found in 12% of the cases 
(Munichor et al., 2000, as cited in Pratap et al., 1984). In another recent case report of 
nasopharyngeal carcinoma with cervical metastasis, the blind biopsies obtained from 
nasopharynx and fine needle aspiration biopsy (FNAB) of the metastatic cervical lymph 
nodes revealed carcinoma with amyloid deposits. Authors draw attention to the fact that a 
potential association of these two conditions may be more frequent than expected and 
diagnosis of carcinoma with amyloidosis can be made with the use of FNAB (Munichor et 
al., 2000). 
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Fig. 5. In the CT scan, the nasopharynx is obliterated by a granular mass with irregular 
borders. No calcification is seen. Histological examination of the lesion revealed amyloidosis 
(Özdemir et al., 2010) 
Sometimes, amyloid tumors in the nasopharynx can be difficult to treat and recur despite 
surgical excision. Less recurrence is reported following laser excision of localized 
amyloidosis (Simpson et al., 1984). Localized nasopharyngeal amyloidosis is a rare disease, 
for which slow progression and spontaneous regression is expected, therefore it is difficult 
to predict the outcome. Recurrent masses and extensive lesions involving the head and neck 
should be handled conservatively (Patel et al., 2002). 
5. Localized sinonasal amyloidosis 
Primary amyloidosis localized to the nose and/or paranasal sinuses is rare with only 27 
reported cases in the English literature (Chin et al., 2004; Mufarrij et al., 1990; Paccalin et al., 
2005; Pang et al., 2001; Prasad et al., 2009; Teo et al., 2003; Tsikoudas et al., 2001). Out of 
these 8 of them are solely localized to the nasal cavity (Pang et al., 2001).  
Smooth, soft to firm, non tender, pale waxy gray, yellow or pale pink masses of amyloid 
deposits are found localized to the inferior concha or other parts of the lateral wall, the 
septum (Figure 6). The diagnostic nasal endoscopy is helpful in exploring yellowish 
polypoidal masses extending to the choana, though radiological imaging defines the disease 
more thoroughly (Prasad et al., 2009). Amyloid deposits are composed of AL, kappa or 
lambda light chain amyloid. Clinical presentation is often insidious, with symptoms that are 
slowly progressive over months to years prior to diagnosis. Presenting symptoms are nasal 
obstruction, nasal discharge, epistaxis and glue ear; facial pain and neuralgia can be seen in 
amyloidosis of the maxillary antrum (Paccalin et al., 2005; Pang et al., 2001).  
The extent of the localized disease is best evaluated by CT and/or MRI scans. In CT scans, 
calcification seems to be a nonspecific finding. Besides this, in the paranasal sinuses, a 
“fluffy” appearance is noted in the sinonasal cavity bones adjacent to the amyloid deposits 
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in a case. This could be a result of an osteoblastic reaction incited by the deposition of the 
proteinaceous amyloid fibrils in the submucosal layers of the sinonasal cavities. Although 
sinonasal calcifications can also be seen in inspissated secretions, fungal mycetomas, 
cartilaginous tumors, and olfactory neuroblastomas, the “fluffy” bone changes have not 
been seen with these diseases (Chin et al., 2004). 
 
 
Fig. 6. Amyloid deposits beneath nasal mucosa (hematoxylin eosin) (Prasad et. al., 2009) 
Systemic disease should be excluded with appropriate tests. Multifocal involvement is 
possible therefore endoscopic examination of the entire respiratory tract is indicated 
including nasopharynx, oropharynx, larynx and tracheobronchial tree. Medical treatment 
has been unsuccessful and radiotherapy is ineffective and contraindicated in this region. 
When the disease is symptomatic, conservative surgery is the only option, however 
recurrences are common (Tsikoudas et al., 2001). Simpson et al. reported that complete 
excision using the CO2 laser was satisfactory with no recurrence in a 14-year follow-up 
period, whereas incomplete excision resulted in recurrence (Simpson et al., 1984). 
6. Localized amyloidosis of the oral cavity and oropharynx 
Oral amyloidosis often appears with a variety of manifestations, such as multiple soft 
nodules that appear hemorrhagic or pink to yellow. Amyloidosis presents as a diffuse or a 
nodular mass mimicking a neoplasm such as granular cell tumors, schwannomas, 
neurofibromas and mucosal neuromas (Asaumi et al., 2001). 
The tongue is the most frequently observed oral subsite, which almost always suggests 
systemic disease. This can cause a firm or rubbery macroglossia, manifested by increased 
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tongue volume, tongue protrusion beyond the alveolar ridge, speech impairment, and 
dysphagia (Fahrner et al., 2004). The patients with macroglossia typically demonstrate 
scalloping of the lateral border of the tongue due to indentations from the teeth (Penner & 
Muller, 2006). Yellow nodules or raised white lesions occurring predominately along the 
lateral border are also common (Fahrner et al., 2004). Sometimes petechiae, ecchymoses and 
hemorrhagic blisters can also be observed. The tongue involvement with numerous smooth 
surfaced, white-yellow nodules has been reported in cases of long term dialysis related 
amyloidosis (Pentenero et al., 2006). Amyloid of the tongue is usually secondary to primary 
amyloidosis with plasma cell dyscrasia, consisting of the monoclonal AL immunoglobulin 
light-chain amyloid. Additionally, macroglossia occurs in 26% to 83% of patients with 
multiple myeloma. For generalized macroglossia, besides amyloidosis; tuberculosis, 
lymphangioma, hypothyroidism, acromegaly, lingual infarction caused by giant-cell 
arteritis, idiopathic muscular hypertrophy, and Beckwith-Wiedemann syndrome should be 
considered in the differential diagnosis.  
Localized amyloidosis of the tongue is rare and associated with AL type amyloidosis. So far, 
only thirteen cases have been reported in the English literature. (Biewend et al., 2006; 
Fahrner et al.,2004; Koren et al., 1998; Penner & Muller, 2006; Simpson et al., 1984), although 
for four of these cases, a full evaluation for systemic disease was not documented. One of 
these cases was reported to develop Hodgkin’s lymphoma 12 years after the diagnosis of 
localized amyloidosis (Penner CR & Muller S (2006). Two of the cases presented with 
glossodynia and glossopyrosis with lesions which were thought to represent median 
rhomboid glossitis (Koren et al., 1998; Yamoka et al., 1978). One other patient presented with 
pyrosis of tongue and a well-circumscribed, rubbery, nodular mass in the tongue base 
(Akyıldız et al, 2009). Others had discrete, firm, pink to yellowish, multiple or solitary 
nodular lesions on the tongue (Penner & Muller, 2006). For nodular localized lesions, 
fibroma, lipoma, granular cell tumor, sarcoma, and salivary gland tumors are among the 
differential. MR images of tongue involvement of amyloidosis appear slightly low on T1-
weighted images and slightly high on T2-weighted images compared with T1-T2 images of 
residual normal tongue (Asaumi et al., 2001). 
Localized amyloid of the tonsil is also rare and, to date there have only been thirteen reports 
in the world literature.(Green et al., 2000; López et al., 1996; Passerotti et al., 2008; Tsuji et al., 
2008) Four of these cases also involve other parts of the Waldeyer’s ring. (Green et al., 2000; 
Passerotti et al., 2008) In four reports amyloid was found to affect both tonsils (Green et al., 
2000). Immunohistochemical investigations undertaken in some of the reports revealed AL 
type amyloidosis (López et al., 1996; Tsuji et al., 2008) 
Localized amyloidosis of other sites of the oral cavity is extremely rare. Only 5 cases of 
localized amyloidosis involving palate have been reported to date. (Aono et al., 2009; 
Pentenero et al., 2006) One of these cases was found to be AA type of amyloidosis while 
others were AL type. Even though AA type of amyloidosis is usually secondary to chronic 
inflammatory diseases, the systemic work-up for this case was negative, and the case was 
considered a primary localized involvement of the palate. The authors hypothesized the role 
of the denture as a local chronic irritant agent (Pentenero et al., 2006). Lips (Simpson et al., 
1984), gingiva (Maulin et al., 1997), lateral pharyngeal wall (Penner & Muller 2006), floor of 
the mouth (Simpson et al., 1984) are other sites involved in various reports. 
Although the presentation seems localized, amyloidosis of head and neck mucosal sites 
excluding larynx is often secondary to an underlying malignancy. In a series of 12 cases 
involving the tongue, pharynx, and cervical lymph nodes, 9 (78%) were associated with 
malignancy or plasma cell dyscrasia. A referral to a hematologist is appropriate when a 
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patient presents with lingual amyloidosis or other head and neck sites to exclude 
malignancy or systemic disease (Penner & Muller, 2006).  
7. Localized amyloidosis of other sites of head and neck 
Although the parotid gland has been suggested as a possible site of involvement in systemic 
amyloidosis, only three cases of localized amyloid tumor involving the parotid gland without 
systemic involvement has been reported in the literature (Stimson et al., 1988; Nandapalan et 
al., 1998; Biewend et al., 2006). The immunohistochemical work-up for the first case 
demonstrated staining for immunoglobulin A, lambda and kappa light chains within the 
amyloid deposits and in the cytoplasm of the lymphocytes, and plasma cell aggregates 
(Stimson et al., 1988). The second case presented with enlarging, painless swelling of the right 
parotid region. FNAB of the mass nondiagnostic, but an MRI scan of the head and neck 
showed that both parotid glands were involved. A right parotidectomy for histological 
diagnosis was given, and the patient was asymptomatic in the follow-up (Nandapalan et al., 
1998). The third case presented with the involvement of both parotid and submandibular 
glands. The lesions were excised and no recurrence was observed (Biewend et al., 2006). 
As far as salivary structures are concerned, one other case of primary localized amyloidosis 
of the sublingual gland is reported. This case is also the first case of the oral cavity with 
primary localized amyloidosis consisting AA protein (Kurokawa et al., 1998). 
Many cases of cutaneous amyloidosis have been reported in the literature, but only 4 
primary localized cases involving the external auditory canal, and one case involving both 
external and middle ear were reported. The latter case was diagnosed with the biopsy of the 
external canal and the CT images of the middle ear were similar to the mass in the external 
ear canal. The patient was treated with regular cleansing and debridement of the ear canal 
to prevent irritation, deafness and secondary infection. The authors were reluctant to 
explore the middle ear, fearing to provoke postoperative dizziness or tinnitus, for this could 
end the patient’s job as a roofer. Fourteen months after diagnosis, the disease remained 
confined to the involved ear (Gheriani et al., 2007). In the English literature, two other cases 
of hemodialysis-associated amyloidosis localized to external auditory canal have been 
reported (Yamazaki et al., 2011). Treatment should include local excision and debridement 
to prevent irritation, deafness, and secondary infection. Topical steroid therapy can also 
help limit the local inflammatory process (Gheriani et al., 2007). 
To date, eight cases of primary cutaneous amyloidosis involving the auricular concha have 
been reported (Shimauchi et al., 2006). The nodules which appear pink to brown or red, are 
typically non-pruritic, slightly friable, but tend not to ulcerate. They may be present on both 
ears. This entity appears to have been described previously as collagenous papules of the 
ear. The patients do not have lesions of amyloidosis on other parts of the body and no 
systemic involvement is seen (Hicks et al., 1988). Skin biopsy provides the definitive 
diagnosis. An optimal biopsy specimen includes the epidermis, papillary dermis, and 
reticular dermis. The amyloid in nodular localized cutaneous amyloidosis is located in the 
reticular dermis and subcutaneous fat, and clearly differentiates nodular localized 
cutaneous amyloidosis from other forms of amyloidosis. A shave biopsy or other superficial 
samples may not include enough reticular dermis to complete the diagnosis (Biesbroeck & 
Kauffman, 2010). Histologically amorphous materials are present in the widened dermal 
papillae positive for Congo red (Shimauchi et al., 2006). Procedures such as excision, 
curettage and electrodesiccation as well as laser treatment have provided satisfactory 
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cosmetic results for nodular localized cutaneous amyloidosis. None of these treatment 
methods totally eradicates lesions, which can recur (Biesbroeck & Kauffman, 2010). 
Nodular localized primary cutaneous amyloidosis of the nose is very rare and five cases 
have been reported to date (Biewend et al., 2006; Blanc et al., 1985; Evers et al., 2007; Kakani 
et al., 2001) Nodular amyloidosis can be treated successfully with cold steel excision in 
combination with carbon dioxide laser. Cases of nodular localized cutaneous amyloidosis of 
the neck present with multiple subcutaneous neck nodules. A literature review showed five 
reported cases of subcutaneous nodular amyloidosis. Immunohistochemical analysis in one 
of these cases showed the amyloid deposits consisting of AL lambda light chains. Twenty-
four months follow-up in this case showed minimal disease progression (Nguyen et al., 2001). 
Finally, amyloid may infiltrate the thyroid or other endocrine glands, but rarely causes 
endocrine dysfunction. However, local amyloid deposition in the thyroid gland is noted to 
have a close association with medullary carcinoma, being present in the stroma of 75% of 
medullary carcinoma. Therefore, a neck mass revealing amyloid should be investigated to 
rule out occult medullary carcinoma of the thyroid gland. (Nandapalan et al, 1998). 
8. Conclusion 
Localized amyloidosis in the head and neck is a benign disease, and should be differentiated 
from localized involvement of a systemic disease. Upper aerodigestive tract can be involved 
in 90% of the patients with systemic amyloidosis. Owing to its poor prognosis, the latter 
condition as well as localized amyloidosis should be recognized by otolaryngologists, and 
systemic investigations should be encountered in order to differentiate localized from 
systemic amyloidosis. Localized amyloidosis of head and neck tend to recur, and it usually 
takes a number of years until the disease is stabilized, therefore conservative management is 
the rule. If the disease is symptomatic, conservative surgery is essential, and yearly follow-
ups are recommended for at least 10 years. Local recurrences should be treated as 
conservative as possible. Asymptomatic disease usually requires no intervention. In the 
follow-ups, systemic amyloidosis should never be ruled out from the differential diagnosis. 
Early monitoring of the presence of monoclonal free light chains in serum and urine might 
be helpful in detecting progression into systemic amyloidosis at an earlier stage of the 
disease. Finally, localized amyloidosis of the head and neck is rare, therefore publication of 
more cases should be encouraged in order to contribute to the literature and develop 
appropriate strategies for management. 
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Amyloidosis is a benign, slowly progressive condition characterized by the presence of extracellular fibrillar
proteins in various organs and tissues. It has systemic or localized forms. Both systemic and localized
amyloidosis have been a point of interest for many researchers and there have been a growing number of
case reports in the literature for the last decade. The aim of this book is to help the reader become familiar
with the presentation, diagnosis and treatment modalities of systemic and localized amyloidosis of specific
organs or systems and also cover the latest advancements in therapy.
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